Europe
With fresh two-year data in hand, Novartis remains focused on seeking regulatory approval for brolucizumab, an ophthalmology drug for the treatment of neo-vascular age related macular degeneration..
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NASH, because it has several components.
As the acquisition of Shire by Takeda Pharmaceutical inches forward, global regulatory agencies are signing off on the deal. As the European Commission (EC) conducts a review of the deal, it hit a snag.
D3A will support important research projects with potential to create meaningful new medicines for dementia
Abingworth today announced that Jackie Grant, PhD, MBA, will join Abingworth as a Principal based in the company’s Boston office. Jackie has more than 10 years of scientific, research and business development experience.
Product and Service revenue up 29% year-on-year
Sudden unexpected death in epilepsy (SUDEP) occurs in approximately 1/1000 people with epilepsy and is poorly understood
Routine corticosteroid treatment correlates with increased mortality and decreased Traumakine efficacy
Immunicum AB announced today that the Company will participate in and host investor events in October and November.
More than 120 attendees gathered from the 17th to 18th October in Hannover for the European Business Development Conference (EBDC), the yearly biotech partnering event of the German biotechnology industry association BIO Deutschland.
PRESS RELEASES